# Orchestra BioMed Holdings, Inc.: financial statements, quarterly

OBIO · Nasdaq · CIK 1814114 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/obio.md) · [Financials](/companies/obio/financials.md) · [Filings](/companies/obio/filings.md) · [Insiders](/companies/obio/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/obio/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.4](/filings/0001558370-24-015313.md) | [0.3 d](/filings/0001558370-25-004161.md) | [0.6](/filings/0001558370-25-007373.md) | [0.8](/filings/0001558370-25-011148.md) | [1.0](/filings/0001104659-25-109128.md) | [0.3 d](/filings/0001104659-26-026754.md) | [0.9](/filings/0001104659-26-059382.md) | [0.8](/filings/0001104659-26-093357.md) | [0.9](/filings/0001104659-25-109128.md) | [30.9 d](/filings/0001104659-26-026754.md) | [0.1](/filings/0001104659-26-059382.md) | [0.1](/filings/0001104659-26-093357.md) |
| Cost of revenue | $m | [0.0](/filings/0001558370-24-015313.md) | [0.0 d](/filings/0001558370-25-004161.md) | [0.0](/filings/0001558370-25-007373.md) | [0.0](/filings/0001558370-25-011148.md) | [0.1](/filings/0001104659-25-109128.md) | [0.1 d](/filings/0001104659-26-026754.md) | [0.0](/filings/0001104659-26-059382.md) | [0.0](/filings/0001104659-26-093357.md) | [0.0](/filings/0001104659-25-109128.md) | [0.1 d](/filings/0001104659-26-026754.md) | [0.0](/filings/0001104659-26-059382.md) | [0.0](/filings/0001104659-26-093357.md) |
| Research and development | $m | [8.6](/filings/0001558370-24-015313.md) | [8.5 d](/filings/0001558370-25-004161.md) | [9.1](/filings/0001558370-25-007373.md) | [11.1](/filings/0001558370-25-011148.md) | [11.6](/filings/0001104659-25-109128.md) | [11.0 d](/filings/0001104659-26-026754.md) | [13.5](/filings/0001104659-26-059382.md) | [13.9](/filings/0001104659-26-093357.md) | [14.0](/filings/0001104659-25-109128.md) | [16.8 d](/filings/0001104659-26-026754.md) | [15.8](/filings/0001104659-26-059382.md) | [16.6](/filings/0001104659-26-093357.md) |
| Selling, general and administrative | $m | [6.3](/filings/0001558370-24-015313.md) | [4.2 d](/filings/0001558370-25-004161.md) | [5.9](/filings/0001558370-25-007373.md) | [6.5](/filings/0001558370-25-011148.md) | [5.7](/filings/0001104659-25-109128.md) | [5.9 d](/filings/0001104659-26-026754.md) | [6.3](/filings/0001104659-26-059382.md) | [6.3](/filings/0001104659-26-093357.md) | [7.1](/filings/0001104659-25-109128.md) | [7.3 d](/filings/0001104659-26-026754.md) | [6.4](/filings/0001104659-26-059382.md) | [5.8](/filings/0001104659-26-093357.md) |
| Operating income | $m | [(14.5)](/filings/0001558370-24-015313.md) | [(12.5) d](/filings/0001558370-25-004161.md) | [(14.4)](/filings/0001558370-25-007373.md) | [(16.9)](/filings/0001558370-25-011148.md) | [(16.3)](/filings/0001104659-25-109128.md) | [(16.7) d](/filings/0001104659-26-026754.md) | [(18.9)](/filings/0001104659-26-059382.md) | [(19.3)](/filings/0001104659-26-093357.md) | [(20.3)](/filings/0001104659-25-109128.md) | [6.8 d](/filings/0001104659-26-026754.md) | [(22.1)](/filings/0001104659-26-059382.md) | [(22.4)](/filings/0001104659-26-093357.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(13.3)](/filings/0001558370-24-015313.md) | [(12.8) d](/filings/0001558370-25-004161.md) | [(13.5)](/filings/0001104659-25-109128.md) | [(16.0)](/filings/0001104659-25-109128.md) | [(15.4)](/filings/0001104659-25-109128.md) | [(16.2) d](/filings/0001104659-26-026754.md) | [(18.8)](/filings/0001104659-26-093357.md) | [(19.4)](/filings/0001104659-26-093357.md) | [(20.8)](/filings/0001104659-25-109128.md) | [6.2 d](/filings/0001104659-26-026754.md) | [(20.7)](/filings/0001104659-26-093357.md) | [(23.8)](/filings/0001104659-26-093357.md) |
| Diluted EPS | $ per share | [(0.38)](/filings/0001558370-24-015313.md) | not reported | [(0.38)](/filings/0001558370-25-007373.md) | [(0.45)](/filings/0001558370-25-011148.md) | [(0.41)](/filings/0001104659-25-109128.md) | not reported | [(0.49)](/filings/0001104659-26-059382.md) | [(0.50)](/filings/0001104659-26-093357.md) | [(0.40)](/filings/0001104659-25-109128.md) | not reported | [(0.33)](/filings/0001104659-26-059382.md) | [(0.38)](/filings/0001104659-26-093357.md) |
| Basic EPS | $ per share | [(0.38)](/filings/0001558370-24-015313.md) | not reported | [(0.38)](/filings/0001558370-25-007373.md) | [(0.45)](/filings/0001558370-25-011148.md) | [(0.41)](/filings/0001104659-25-109128.md) | not reported | [(0.49)](/filings/0001104659-26-059382.md) | [(0.50)](/filings/0001104659-26-093357.md) | [(0.40)](/filings/0001104659-25-109128.md) | not reported | [(0.33)](/filings/0001104659-26-059382.md) | [(0.38)](/filings/0001104659-26-093357.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [19.1](/filings/0001558370-23-018829.md) | [30.6](/filings/0001558370-25-004161.md) | [23.3](/filings/0001558370-24-007978.md) | [23.7](/filings/0001558370-24-011899.md) | [25.6](/filings/0001558370-24-015313.md) | [22.3](/filings/0001104659-26-026754.md) | [18.3](/filings/0001558370-25-007373.md) | [18.7](/filings/0001558370-25-011148.md) | [42.0](/filings/0001104659-25-109128.md) | [34.7](/filings/0001104659-26-093357.md) | [28.4](/filings/0001104659-26-059382.md) | [20.5](/filings/0001104659-26-093357.md) |
| Current assets | $m | [110](/filings/0001558370-23-018829.md) | [89.1](/filings/0001558370-25-004161.md) | [76.4](/filings/0001558370-24-007978.md) | [66.5](/filings/0001558370-24-011899.md) | [68.6](/filings/0001558370-24-015313.md) | [69.2](/filings/0001104659-26-026754.md) | [51.9](/filings/0001558370-25-007373.md) | [35.9](/filings/0001558370-25-011148.md) | [97.8](/filings/0001104659-25-109128.md) | [108](/filings/0001104659-26-093357.md) | [96.2](/filings/0001104659-26-059382.md) | [111](/filings/0001104659-26-093357.md) |
| Total assets | $m | [116](/filings/0001558370-23-018829.md) | [95.2](/filings/0001558370-25-004161.md) | [82.6](/filings/0001558370-24-007978.md) | [72.4](/filings/0001558370-24-011899.md) | [75.3](/filings/0001558370-24-015313.md) | [76.2](/filings/0001104659-26-026754.md) | [59.1](/filings/0001558370-25-007373.md) | [42.8](/filings/0001558370-25-011148.md) | [105](/filings/0001104659-25-109128.md) | [115](/filings/0001104659-26-093357.md) | [101](/filings/0001104659-26-059382.md) | [116](/filings/0001104659-26-093357.md) |
| Current liabilities | $m | [21.5](/filings/0001558370-23-018829.md) | [11.2](/filings/0001558370-25-004161.md) | [10.4](/filings/0001558370-24-007978.md) | [14.5](/filings/0001558370-24-011899.md) | [16.2](/filings/0001558370-24-015313.md) | [16.2](/filings/0001104659-26-026754.md) | [15.5](/filings/0001558370-25-007373.md) | [17.1](/filings/0001558370-25-011148.md) | [20.7](/filings/0001104659-25-109128.md) | [16.7](/filings/0001104659-26-093357.md) | [13.7](/filings/0001104659-26-059382.md) | [13.5](/filings/0001104659-26-093357.md) |
| Total liabilities | $m | [36.7](/filings/0001558370-23-018829.md) | [27.2](/filings/0001558370-25-004161.md) | [25.4](/filings/0001558370-24-007978.md) | [28.3](/filings/0001558370-24-011899.md) | [29.1](/filings/0001558370-24-015313.md) | [43.2](/filings/0001104659-26-026754.md) | [42.2](/filings/0001558370-25-007373.md) | [42.5](/filings/0001558370-25-011148.md) | [61.1](/filings/0001104659-25-109128.md) | [51.5](/filings/0001104659-26-093357.md) | [49.7](/filings/0001104659-26-059382.md) | [86.3](/filings/0001104659-26-093357.md) |
| Long-term debt | $m | [10.0](/filings/0001558370-23-018829.md) | not reported | not reported | not reported | not reported | [15.0](/filings/0001558370-25-004161.md) | [15.0](/filings/0001558370-25-007373.md) | [15.0](/filings/0001558370-25-011148.md) | [15.0](/filings/0001104659-25-109128.md) | [15.0](/filings/0001104659-26-026754.md) | [15.0](/filings/0001104659-26-059382.md) | not reported |
| Shareholders' equity | $m | [79.7](/filings/0001558370-24-015313.md) | [68.0](/filings/0001104659-26-026754.md) | [57.2](/filings/0001104659-25-109128.md) | [44.1](/filings/0001104659-25-109128.md) | [46.2](/filings/0001104659-25-109128.md) | [33.0](/filings/0001104659-26-093357.md) | [16.9](/filings/0001104659-26-093357.md) | [0.3](/filings/0001104659-26-093357.md) | [43.7](/filings/0001104659-25-109128.md) | [53.6](/filings/0001104659-26-093357.md) | [41.2](/filings/0001104659-26-093357.md) | [19.3](/filings/0001104659-26-093357.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(10.3) d](/filings/0001558370-24-015313.md) | [(11.0) d](/filings/0001558370-25-004161.md) | [(13.1)](/filings/0001558370-25-007373.md) | [(10.2) d](/filings/0001558370-25-011148.md) | [(13.7) d](/filings/0001104659-25-109128.md) | [(13.5) d](/filings/0001104659-26-026754.md) | [(16.6)](/filings/0001104659-26-059382.md) | [(15.5) d](/filings/0001104659-26-093357.md) | [(14.6) d](/filings/0001104659-25-109128.md) | [(2.3) d](/filings/0001104659-26-026754.md) | [(22.2)](/filings/0001104659-26-059382.md) | [(19.3) d](/filings/0001104659-26-093357.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001558370-24-015313.md) | [(0.0) d](/filings/0001558370-25-004161.md) | [0.0](/filings/0001558370-25-007373.md) | [0.1 d](/filings/0001558370-25-011148.md) | [0.1 d](/filings/0001104659-25-109128.md) | [0.1 d](/filings/0001104659-26-026754.md) | [0.1](/filings/0001104659-26-059382.md) | [0.0 d](/filings/0001104659-26-093357.md) | [0.3 d](/filings/0001104659-25-109128.md) | [0.0 d](/filings/0001104659-26-026754.md) | [0.2](/filings/0001104659-26-059382.md) | [0.3 d](/filings/0001104659-26-093357.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [20.2](/filings/0001558370-23-018829.md) | [27.6](/filings/0001558370-24-007978.md) | [34.6](/filings/0001558370-24-011899.md) | [35.2](/filings/0001558370-24-015313.md) | [35.8](/filings/0001558370-25-007373.md) | [35.8](/filings/0001558370-25-011148.md) | [37.6](/filings/0001104659-25-109128.md) | [38.2](/filings/0001104659-26-059382.md) | [38.4](/filings/0001104659-26-093357.md) | [52.2](/filings/0001104659-25-109128.md) | [62.7](/filings/0001104659-26-059382.md) | [63.8](/filings/0001104659-26-093357.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 60,105,049 at 2026-08-06, from the cover of the [10-Q filed 2026-08-10](/filings/0001104659-26-093357.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.